Shares of BeyondSpring Inc. (NASDAQ:BYSI) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokers have set a 12-month consensus target price of $56.00 for the company and are predicting that the company will post ($0.79) EPS for the current quarter, according to Zacks. Zacks has also given BeyondSpring an industry rank of 111 out of 265 based on the ratings given to related companies.

A number of equities research analysts have issued reports on BYSI shares. Zacks Investment Research raised shares of BeyondSpring from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of BeyondSpring in a research note on Monday, August 21st. Finally, Maxim Group started coverage on shares of BeyondSpring in a research note on Tuesday, August 22nd. They issued a “buy” rating and a $52.00 price objective for the company.

A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new stake in BeyondSpring Inc. (NASDAQ:BYSI) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring comprises 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring at the end of the most recent reporting period. Institutional investors and hedge funds own 1.23% of the company’s stock.

Shares of BeyondSpring (NASDAQ BYSI) traded up $0.88 during trading hours on Wednesday, hitting $35.25. 860 shares of the company’s stock were exchanged, compared to its average volume of 5,648. BeyondSpring has a 52 week low of $16.55 and a 52 week high of $48.49.

BeyondSpring (NASDAQ:BYSI) last issued its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. equities research analysts expect that BeyondSpring will post -4.41 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “BeyondSpring Inc. (BYSI) Given $56.00 Average Target Price by Analysts” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related stocks with our FREE daily email newsletter.